This is a critical checkpoint
These predispositions do not predict your exact response to semaglutide or tirzepatide, but they may help provide context for provider decision-making about dose escalation, medication selection, or potential side-effect risk
A randomized, double-blind, phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers
the provider does not need to be Medicare-enrolled) Receive prior authorization from your Part D plan, which is the standard pre-approval process Medicare uses for covered medications Patients who initiated GLP-1 therapy before the Bridge Program launched can still qualify if they met the BMI criteria at the time therapy was initiated, even if their current BMI is now lower (a common situation for patients who have already achieved meaningful weight loss)
Identify your caregiver Your caregiver has an important role in your care